Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
This study (n=26) found that ayahuasca decreased convergent thinking (a part of creativity) on very experienced participants in an ayahuasca ceremony. The conclusion about divergent thinking (increased) was found on only one of the measures (ratio).
Authors
- Jordi Riba
- Kim Kuypers
- Johannes Ramaekers
Published
Abstract
Introduction
Ayahuasca is a South American psychotropic plant tea traditionally used in Amazonian shamanism. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine oxidase-inhibiting properties. Increasing evidence from anecdotal reports and open-label studies indicates that ayahuasca may have therapeutic effects in treatment of substance use disorders and depression. A recent study on the psychological effects of ayahuasca found that the tea reduces judgmental processing and inner reactivity, classic goals of mindfulness psychotherapy. Another psychological facet that could potentially be targeted by ayahuasca is creative divergent thinking. This mode of thinking can enhance and strengthen psychological flexibility by allowing individuals to generate new and effective cognitive, emotional, and behavioral strategies. The present study aimed to assess the potential effects of ayahuasca on creative thinking.
Methods
We visited two spiritual ayahuasca workshops and invited participants to conduct creativity tests before and during the acute effects of ayahuasca. In total, 26 participants consented. Creativity tests included the Bpattern/line meanings test^ (PLMT) and the Bpicture concept test^ (PCT), both assessing divergent thinking and the latter also assessing convergent thinking.
Results
While no significant effects were found for the PLMT, ayahuasca intake significantly modified divergent and convergent thinking as measured by the PCT. While convergent thinking decreased after intake, divergent thinking increased.
Conclusions
The present data indicate that ayahuasca enhances creative divergent thinking. They suggest that ayahuasca increases psychological flexibility, which may facilitate psychotherapeutic interventions and support clinical trial initiatives.
Research Summary of 'Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking'
Introduction
Ayahuasca is a traditional South American plant brew that contains the serotonergic 5-HT2A agonist N,N-dimethyltryptamine (DMT) together with monoamine oxidase–inhibiting β-carboline alkaloids, rendering oral DMT active. Earlier work has reported acute visionary effects, mixed findings on cognition depending on user experience, no evidence of long-term cognitive harm in follow-up studies, and potential therapeutic benefits for substance use disorders and depression. Psychedelics more broadly have been associated with lasting changes in well‑being and reductions in psychological distress in population surveys. Separate studies indicate that ayahuasca can enhance mindfulness-related capacities and reduce judgmental processing, and neuroimaging work has found altered connectivity in networks implicated in cognition and perception after ayahuasca ingestion. Kuypers and colleagues framed creative thinking—distinguishing divergent thinking (generating many novel ideas) from convergent thinking (finding a single correct solution)—as a psychological facet that could be modulated by ayahuasca and might contribute to therapeutic change through increased psychological flexibility. The present quasi‑experimental study therefore set out to assess whether acute ayahuasca intake alters divergent and convergent creative thinking. Creativity was measured before and during the acute inebriation in two separate ayahuasca‑using groups to test whether effects were robust across settings and participant characteristics.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Kuypers, K. P. C., Riba, J., de la Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016). Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology, 233(18), 3395-3403. https://doi.org/10.1007/s00213-016-4377-8
References (24)
Papers cited by this study that are also in Blossom
Alonso, J. N., Romero, S., Mañanas, M. A. et al. · International Journal of Neuropsychopharmacology (2015)
Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M. et al. · Psychopharmacology (2013)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Brain Research Bulletin (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Frecska, E., Móré, C. E., Vargha, A. et al. · Journal of Psychoactive Drugs (2012)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)
Show all 24 referencesShow fewer
Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E. et al. · Psychopharmacology (1999)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Hasler, F., Grimberg, U., Benz, M. A. et al. · Psychopharmacology (2004)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
McKenna, D. · ACS Chemical Neuroscience (2004)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Riba, J., Rodríguez-Fornells, A., Barbanoj, M. J. · Psychopharmacology (2002)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)
Sessa, B., Johnson, M. W. · British Journal of Psychiatry (2018)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)
Cited By (62)
Papers in Blossom that reference this study
Silva-Costa, N., Pessoa, J. A., Andrade, K. C. et al. · Journal of Psychopharmacology (2025)
Prochazkova, L., van Elk, M., Marschall, J. et al. · Neuropsychopharmacology (2025)
Soto-Angona, Ó., Andión, O., Sabucedo, P. et al. · Scientific Reports (2025)
Suay, D., Aicher, H. D., Singer, B. et al. · Journal of Psychopharmacology (2025)
Tylš, F., Páleníček, T., Klučková, T. et al. · Pharmacological Reports (2025)
Murphy, R. J. · Psychopharmacology (2024)
Solaja, I., Haldane, K., Mason, N. et al. · Neuroscience and Biobehavioral Reviews (2024)
De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)
Ramaekers, J. G., Mallaroni, P., Kloft, L. et al. · Journal of Cognitive Neuroscience (2023)
Nardou, R., Sawyer, E., Song, Y. J. et al. · Nature (2023)
Show all 62 papersShow fewer
Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2023)
Spriggs, M. J., Murphy-Beiner, A., Murphy, R. et al. · Psychological Medicine (2022)
Bouso, J. C., Andión, O., Sarris, J. et al. · PLOS Global Public Health (2022)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Costa, M. A. · Journal of Psychoactive Drugs (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Forstmann, M., Sagioglou, C. · European Psychologist (2022)
Balaet, M. · Frontiers in Neuroscience (2022)
Wießner, I., Falchi, M., Maia, L. O. et al. · Journal of Psychopharmacology (2022)
Barker, S. A. · Psychopharmacology (2022)
Maia, L. O., Feilding, A., Ribeiro, S. et al. · Psychopharmacology (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)
Davis, A. K., Xin, Y., Sepeda, N. D. et al. · Chronic Stress (2021)
Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2021)
Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
Pallavicini, C., Cavanna, F., Zamberlan, F. et al. · Journal of Psychopharmacology (2021)
O'shaughnessy, D. M., Berlowitz, I., Rodd, R. et al. · Therapeutic Advances in Psychopharmacology (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Ona, G., Bouso, J. C. · Neuroscience and Biobehavioral Reviews (2020)
Kangaslampi, S., Hausen, A., Rauteenmaa, T. · Journal of Psychoactive Drugs (2020)
Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)
Heuschkel, K., Kuypers, K. P. C. · Frontiers in Psychiatry (2020)
Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)
Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M. et al. · Psychopharmacology (2020)
Murphy-Beiner, A., Soar, K. · Psychopharmacology (2020)
Agin-Liebes, G. I., Malone, T., Yalch, M. M. et al. · Journal of Psychopharmacology (2020)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Scott, G., Carhart-Harris, R. L. · Neuroscience of Consciousness (2019)
Erritzoe, D., Smith, J. M., Fisher, P. M. et al. · Journal of Psychopharmacology (2019)
Mason, N. L., Mischler, E., Uthaug, M. V. et al. · Journal of Psychoactive Drugs (2019)
Prochazkova, L., Lippelt, D. P., Colzato, L. S. et al. · Psychopharmacology (2018)
Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Kuypers, K. P. C. · Medical Hypotheses (2018)
Franquesa, A., Sainz-Cort, A., Gandy, S. et al. · Psychiatry Research (2018)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Hartogsohn, I. · Frontiers in Human Neuroscience (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Winkelman, M. J. · Frontiers in Neuroscience (2017)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Kaelen, M. · Imperial College London (2017)
Sweat, N. W., Bates, L. W., Hendricks, P. S. · Journal of Psychoactive Drugs (2016)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.